Clinical trials: Vinorelbine
Metastatic Breast Cancer, HRD-Positive/HER2-Negative Advanced Breast Cancer
Fluorizoparib Plus Apatinib Versus Chemotherapy in HRD-positive, HER2-negative Advanced Breast Cancer
This is a Phase III clinical trial for patients with a specific type of advanced breast cancer that is HER2-negative and has a biomarker called "Homologous Recombination Deficiency (HRD)-positive." The study aims to compare the…
- Trial name
- NCT07371910
- Testing
- Chemotherapy/ADC Regimen, Fluorizoparib, Apatinib
- Where
- China
- Volunteers
- 200 people
- Sponsor
- Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University
Lung Cancer
Study of Paclitaxel, Carboplatin, and Gemcitabine Versus Gemcitabine and Vinorelbine for Non-Small Cell Lung Cancer
The purpose of this study is to compare the effectiveness of the three-drug combination paclitaxel, carboplatin, and gemcitabine to the two-drug combination gemcitabine and vinorelbine in patients with advanced Non-Small Cell…
- Trial name
- NCT00193362
- Testing
- Paclitaxel, Carboplatin, Gemcitabine
- Volunteers
- 200 people
- Sponsor
- SCRI Development Innovations, LLC
Relapsed/Refractory Peripheral T-cell Lymphoma
Chi-GVM Regimen for the Treatment of R/R PTCL
Peripheral T-cell lymphoma (PTCL) is a heterogeneous group of lymphoproliferative diseases caused by mature T cells, accounting for approximately 10% of non-Hodgkin lymphomas (NHL).
- Trial name
- NCT06211881
- Testing
- Chi-GVM
- Where
- China
- Volunteers
- 50 people
- Sponsor
- The First Affiliated Hospital with Nanjing Medical University
Metastatic Breast Cancer
Pyrotinib and Vinorelbine Tartrate Capsules With or Without Inetetamab for First Line Treatment in Patients With Trastuzumab-resistant HER2-positive Advanced Breast Cancer
Trastuzumab resistance, which is a common therapeutic challenge in HER2 positive metastatic breast cancer, is not fully understood. Pyrotinib is an oral tyrosine kinase inhibitor targeting EGFR, HER-2 and HER-4 receptors.
- Trial name
- NCT04963595
- Testing
- Pyrotinib, Vinorelbine, Inetetamab
- Volunteers
- 100 people
- Sponsor
- Zhiyong Yu
Breast Cancer
Phase 2 Trial of AEZS-108 in Chemotherapy Refractory in Triple Negative Breast Cancer
This is a therapeutic exploratory Phase 2 study evaluating AEZS-108 compared to standard single agent cytotoxic chemotherapy (SSCC) as measured by the median time of progression-free survival (PFS) in patients with chemotherapy…
- Trial name
- NCT01698281
- Testing
- AEZS-108, SCCC, Dexamethasone
- Where
- 3 sites in United States, Germany
- Volunteers
- 7 people
- Sponsor
- AEterna Zentaris
Previously Treated Metastatic Non-Small Cell Lung Cancer
Phase II Study of Oxaliplatin and Navelbine for Second-Line Treatment of Advanced NSCLC.
The purpose of this study is to determine the response rate to treatment with oxaliplatin and Navelbine in patients with previously treated NSCLC. Oxaliplatin and Navelbine have not been clinically evaluated yet.
- Trial name
- NCT00238849
- Testing
- Oxaliplatin
- Where
- 2 sites in United States
- Volunteers
- 40 people
- Sponsor
- Integrated Community Oncology Network
Lung Neoplasms, Lung Cancer
CIrculating Tumour DNA in Lung Cancer (CITaDeL): Optimizing Sensitivity and Clinical Utility
This is a prospective observation study in patients with non-small cell lung cancer (NSCLC) starting either cytotoxic chemotherapy or radiation therapy.
- Conditions
- Lung Neoplasms, Lung Cancer, Neoplasm of Lung, Non Small Cell Lung Cancer
- Trial name
- CITaDeL (NCT03986463)
- Testing
- Circulating tumour DNA (ctDNA)
- Where
- Canada
- Volunteers
- 40 people
- Sponsor
- London Health Sciences Centre Research Institute OR Lawson Research Institute of St. Joseph's
HER2 Positive Metastatic Breast Cancer
Exploratory Study of Advanced Breast Cancer in HER2 Positive Patients With Failure of Multi-line Therapy Treated by Combination of Inetetamab (Cipterbin) + PD-1 Inhibitor Combined With Utidelone.
This study plans to explore the efficacy and safety of chemotherapy combined with inetetamab and PD-1 inhibitors in HER2 positive advanced breast cancer who failed to receive trastuzumab and TKIs, and explore the dominant…
- Trial name
- NCT04681287
- Testing
- inetetamab and PD-1 inhibitor combined with chemotherapy.
- Where
- China
- Volunteers
- 46 people
- Sponsor
- Henan Cancer Hospital
Hodgkin Lymphoma
Multicenter Study of Safety and Efficacy of PET-adapted Treatment With Nivolumab, Bendamustine, Gemcitabine, Vinorelbine (Nivo-BeGEV) in Patients With Relapsed/Refractory Hodgkin Lymphoma
Nivolumab is an anti-PD-1 antibody highly effective in patients with relapsed/refractory classical Hodgkin lymphoma. A PET-adapted regimen of nivolumab combined with salvage therapy was shown to induce high response rates and…
- Trial name
- NCT05660993
- Testing
- Nivolumab
- Where
- Russia
- Volunteers
- 50 people
- Sponsor
- National Research Center for Hematology, Russia
Metastatic Breast Cancer
Trastuzumab & Pertuzumab Followed by T-DM1 in MBC
In HER2-positive metastatic breast cancer, trastuzumab based treatment is the standard of care as long as there are no contraindications to trastuzumab.
- Trial name
- NCT01835236
- Testing
- Trastuzumab, Pertuzumab, Paclitaxel
- Where
- 71 sites in France, Germany and 2 more
- Volunteers
- 208 people
- Sponsor
- Swiss Cancer Institute
Adenocarcinoma of Colon, Adenocarcinoma of Rectum
Study of Individualized Therapies Selection for Patients With Metastatic Colorectal Carcinoma According to the Therapeutic
The purpose of this study is to assess the feasibility of selecting personalized therapies for colon cancer patients who have failed standard treatments, using a new methodology based on the determination of a profile of…
- Conditions
- Adenocarcinoma of Colon, Adenocarcinoma of Rectum, Metastatic Disease
- Trial name
- NCT01703910
- Testing
- Arm A chemotherapy, arm B chemotherapy
- Where
- 2 sites in Spain
- Volunteers
- 29 people
- Sponsor
- Centro Nacional de Investigaciones Oncologicas CARLOS III
Breast Cancer
Inetetamab Combined With Pyrotinib Plus Oral Vinorelbine for the Treatment of HER2-positive Metastatic Breast Cancer
In this phase 2 single-arm clinical trial, 30 patients with HER2-positive metastatic breast cancer after progression on trastuzumab are enrolled and receive treatment of Inetetamab plus Pyrotinib plus Oral Vinorelbine.
- Trial name
- NCT05823623
- Testing
- Inetetamab, Pyrotinib, Oral Vinorelbine Tartrate
- Where
- China
- Volunteers
- 30 people
- Sponsor
- The First Affiliated Hospital with Nanjing Medical University
Non-small Cell Lung Cancer Metastatic
Study of Patient Preference for Oral or Intravenous Vinorelbine in the Treatment of Advanced NSCLC
Title: Randomized cross-over study of patient preference for oral or intravenous vinorelbine in the treatment of advanced NSCLC. A phase IV study.
- Trial name
- VIVOS (NCT01848613)
- Testing
- Vinorelbine
- Where
- 8 sites in Italy
- Volunteers
- 120 people
- Sponsor
- Istituto Romagnolo per lo Studio dei Tumori Dino Amadori IRST S.r.l. IRCCS
Lung Neoplasms, Carcinoma
Safety Study of Cetuximab in Combination With Cisplatin and Vinorelbine to Treat Advanced Non-small Cell Lung Cancer
The purpose of the study is to determine if U.S. manufactured Cetuximab can be safely used for the treatment of Non-Small Cell Lung Cancer in combination with Cisplatin and Vinorelbine.
- Conditions
- Lung Neoplasms, Carcinoma, Cancer of the Lung, Non-Small-Cell Lung Carcinoma
- Trial name
- NCT01109524
- Testing
- Cetuximab, Cisplatin, Vinorelbine
- Where
- 22 sites in United States, Canada and 1 more
- Volunteers
- 72 people
- Sponsor
- Eli Lilly and Company
Non-small Cell Lung Cancer(NSCLC)
the"Fuzheng" Therapy of TCM to Improve the Survival Quality of Early-stage NSCLC by Intervening the CTCs
Metastasis is the leading cause of death in patients with lung cancer, and circulating tumor cells(CTCs) play a key role in the process of distant metastasis.
- Trial name
- CTC-TCM-FZ (NCT02603003)
- Testing
- JinFuKang, Cisplatin, Pemetrexed
- Volunteers
- 218 people, healthy volunteers welcome
- Sponsor
- Shanghai University of Traditional Chinese Medicine
Carcinoma, Non-Small-Cell Lung
Efficacy and Safety of DEB-BACE Combined With PD-1 Inhibitors in Stage II/III NSCLC With Standard Treatment Failure
This study is a prospective, multi-center, randomized, open-ended, double-arm clinical study. All eligible patients were randomly assigned to DEB-BACE combined with PD-1 inhibitor (Sindilizumab) treatment group (test group) and…
- Trial name
- NCT05248022
- Testing
- Drug-eluting beads bronchial arterial chemoembolization, Programmed Cell Death Protein 1 Inhibitor
- Volunteers
- 98 people
- Sponsor
- The Central Hospital of Lishui City
Lung Cancer
Combination Chemotherapy Compared With No Treatment Following Surgery in Treating Patients With Non-small Cell Lung Cancer
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. It is not yet known if combination chemotherapy given after surgery is more effective than surgery alone for…
- Trial name
- NCT00002823
- Testing
- cisplatin, etoposide, vinblastine sulfate
- Where
- 123 sites in United States, Argentina and 27 more
- Volunteers
- 3,300 people
- Sponsor
- Gustave Roussy, Cancer Campus, Grand Paris
Peripheral T-Cell Lymphoma
Treatment of PTCL With Aggressive Induction Therapy Followed by Autologous SCT Using Denileukin Diftitox (Ontak)
This study examines the use of denileukin diftitox (Ontak) for patients with peripheral T-cell lymphoma who are candidates for autologous stem cell transplants.
- Trial name
- NCT00632827
- Testing
- Gemcitabine, Navelbine, Doxorubicin Hydrochloride Liposome Injection
- Where
- United States
- Volunteers
- 21 people
- Sponsor
- University of California, San Francisco
HER2-Negative Breast Cancer, Triple Negative Breast Cancer
Eribulin Versus Vinorelbine in Subjects With Locally Recurrent or Metastatic Breast Cancer Previously Treated With Anthracyclines and Taxanes
This study is designed as an open-label randomized parallel two-arm multicenter efficacy, pharmacokinetics and safety study of intravenously administered eribulin versus intravenously administered vinorelbine in Chinese…
- Conditions
- HER2-Negative Breast Cancer, Triple Negative Breast Cancer, Breast Cancer, Cancer of Breast
- Trial name
- NCT02225470
- Testing
- E7389 (Eribulin Mesylate), Vinorelbine injection
- Where
- 35 sites in China
- Volunteers
- 530 people
- Sponsor
- Eisai Co., Ltd.
Non-Squamous Non-Small Cell Lung Cancer
A Feasibility Trial of Avastin (Bevacizumab) in Combination With Concomitant Chemoradiation (Cisplatin and Vinorelbine) in Patients With Locally Advanced Non-Squamous Non-Small Cell Lung Cancer.
This single arm study will assess the feasibility of use, safety and tolerability of Avastin(bevacizumab) in combination with chemoradiation therapy in patients with locally advanced unresectable non-squamous non-small cell lung…
- Trial name
- NCT00773188
- Testing
- bevacizumab [Avastin], cisplatin, vinorelbine
- Where
- 4 sites in Canada
- Volunteers
- 6 people
- Sponsor
- Hoffmann-La Roche